Ascendis Pharma (NASDAQ:ASND) is without doubt one of the most worthwhile progress shares to purchase. On Could 7, Ascendis Pharma reported sturdy monetary outcomes for Q1 2026, reaching a complete income of €247 million. This progress was primarily pushed by YORVIPATH, which generated €197 million, alongside €44 million from SKYTROFA. Moreover, the corporate introduced an settlement to promote its Uncommon Pediatric Illness Precedence Overview Voucher for $187.5 million, additional strengthening its monetary place.
The corporate is experiencing strong business momentum, highlighted by over 1,000 new US affected person enrollments for YORVIPATH and greater than 60 enrollments for YUVIWEL following its early April launch. Ascendis can also be advancing its medical pipeline, together with constructive outcomes from the COACH mixture remedy trial, whereas making the strategic determination to discontinue inner oncology growth to raised align with its long-term focus.
Operational updates for the quarter embrace a transition to buying and selling bizarre shares on the Nasdaq International Choose Market and the complete redemption of its 2028 convertible notes. With a web revenue of €629 million and money reserves of €573 million as of March 31, Ascendis Pharma (NASDAQ:ASND) continues to solidify its position as a number one world biopharmaceutical agency.
Ascendis Pharma (NASDAQ:ASND) develops TransCon-based therapies for unmet medical wants.
Whereas we acknowledge the potential of ASND as an funding, we imagine sure AI shares provide better upside potential and carry much less draw back danger. Should you’re on the lookout for a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring pattern, see our free report on the finest short-term AI inventory.
READ NEXT: 33 Shares That Ought to Double in 3 Years and Cathie Wooden 2026 Portfolio: 10 Finest Shares to Purchase.
Disclosure: None. Comply with Insider Monkey on Google Information.
